Ensysce Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
ENSC$0.36-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $(6,127,290) | $(3,679,090) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Accrued interest | 3,409 | 6,107 | ||
| Change in fair value of liability classified warrants | - | (9,063) | ||
| Consultant compensation | 646,310 | 106,889 | ||
| Stock-based compensation | 10,613 | 203,014 | ||
| Depreciation expense | 13,066 | - | ||
| Changes in operating assets and liabilities: | ||||
| Unbilled receivable | 3,534 | (1,080,864) | ||
| Prepaid expenses and other assets | 1,041,798 | 1,185 | ||
| Accounts payable | (1,355,046) | (314,247) | ||
| Accrued expenses and other liabilities | 300,223 | 351,789 | ||
| Net cash used in operating activities | (5,463,383) | (4,414,280) | ||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of Series B Preferred Stock | 2,000,000 | - | ||
| Transaction costs associated with Series B Preferred Stock issuance | (106,320) | - | ||
| Proceeds from public offerings | - | 1,100,007 | ||
| Proceeds from warrant exercises, net of issuance costs | - | 390,855 | ||
| Proceeds from warrant inducement, net of issuance costs | - | 2,200,012 | ||
| Transaction costs from public offerings | - | (204,193) | ||
| Transaction costs associated with warrant inducements | - | (291,611) | ||
| Repayment of convertible notes | - | - | ||
| Repayment of financed insurance premiums | (63,947) | (71,292) | ||
| Net cash provided by financing activities | 1,829,733 | 3,123,778 | ||
| Decrease in cash and cash equivalents | (3,633,650) | (1,290,502) | ||
| Cash and cash equivalents beginning of period | 4,310,354 | 3,502,077 | ||
| Cash and cash equivalents end of period | $676,704 | $2,211,575 | ||
| Supplemental disclosure of non-cash financing activities: | ||||
| Conversions of 2023 Notes into common stock | $246,169 | $ | - | |
| Transaction costs associated with Series B Preferred Stock under accounts payable and accrued expenses | $65,065 | $ | - | |
| Incremental fair value of April 2025 Warrant Inducement | $ | - | $3,483,420 | |
| Financed insurance premiums | $196,842 | $188,046 | ||
| Transaction costs from public offerings | $ | - | $5,410 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.